Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Biotechnology

Healthcare
$9.38 +0.00%

+$0.00 today

Market cap
$622.71M
Beta
-0.53
P/E (TTM)
-8.8
EPS (TTM)
-$2.59
52W Low $8.48High $24.25

Volume 1.30M

Average 0.54M

BCAX Other Non-current Liabilities

Long-term obligations not reported separately, such as lease or pension liabilities.

Bicara Therapeutics Inc. Common StockNASDAQ: BCAX

Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other non-current liabilities remains negative

Q1 FY2026 other non-current liabilities was $0, compared with $0 a year earlier.

Context

  • Other non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Other non-current liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Other Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Other Non-current Liabilities vs competitors

How BCAX compares with its peers on the latest reported figures

  • BCAX's Mar 2026 other non-current liabilities of $0 is the 2nd highest of the 6 companies compared; the peer median is $0.
  • Other non-current liabilities amounts to 0.0% of total assets for BCAX, versus a peer median of 0.0%.
BCAX Competitors Peer median
Other Non-current Liabilities for BCAX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MGNXMacroGenics, Inc.Mar 2026$69.44M +3428.5%+59.8%31.9%
BCAXBicara Therapeutics Inc. Common StockMar 2026$0 ——0.0%
CGEMCullinan Therapeutics, Inc.Mar 2026$0 ——0.0%
CBIOCrescent Biopharma, Inc.Mar 2026$0 ——0.0%
CMPXCompass Therapeutics, Inc.Mar 2026$0 ——0.0%
CNTXContext Therapeutics Inc.Mar 2026$0 ——0.0%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding BCAX) $0+3428.5%+59.8%0.0%

Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents4.16M230.44M489.71M96.69M
Short-term Investments000318.12M
Net Receivables0000
Inventory0000
Other Current Assets68K100K12.82M7.25M
Total Current Assets4.98M231.07M502.53M422.05M
Property, Plant & Equipment (Net)636K815K845K2.03M
Goodwill0000
Intangible Assets0000
Long-term Investments0000
Tax Assets0059.2M0
Other Non-current Assets1.08M2.09M6.62M6.91M
Total Non-current Assets1.72M2.91M66.66M8.94M
Total Assets6.7M233.98M569.2M430.99M
Account Payables5.14M3.19M4.51M5.52M
Short-term Debt00607K0
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities009.79M22.32M
Total Current Liabilities23.9M15.09M17.99M28.95M
Long-term Debt0000
Deferred Tax Liabilities0059.2M0
Deferred Revenue (Non-current)0000
Other Non-current Liabilities85K17K00
Total Non-current Liabilities85K389K59.33M593K
Total Liabilities23.98M15.47M77.32M29.54M
Common Stock2K2K7K7K
Retained Earnings(101.04M)(153.02M)(221.02M)(358.97M)
Accumulated OCI000243K
Other Stockholders Equity0000
Minority Interest0000
Total Equity(17.28M)218.51M491.88M401.45M
Total Debt0657K738K1.71M
Net Debt(4.16M)(229.78M)(488.97M)(94.98M)

Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Intrinsic Alpha fair value

Locked

Current Price

$9.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.